Tirzepatide's emerging oral health implications demand focused attention in oral medicine practice
Background
Tirzepatide, a novel dual GLP-1R and GIP-R agonist, has revolutionized the management of Type 2 Diabetes Mellitus and obesity due to its potent glucose-lowering and weight-reducing effects. As its clinical adoption expands rapidly, understanding its full spectrum of systemic effects becomes increasingly critical. While cardiovascular and gastrointestinal impacts are well-studied, the specific implications for oral health remain an emerging area of inquiry. Oral medicine practitioners are at the forefront of identifying and managing drug-related oral manifestations, yet comprehensive guidance on tirzepatide's potential effects—such as xerostomia, taste alterations, or impacts on periodontal health—is currently limited. This gap necessitates a focused examination to ensure holistic patient care and to anticipate future challenges in oral health management for patients on these powerful incretin mimetics.
Why It Matters
Oral medicine practitioners must proactively assess and manage potential oral health changes in patients using tirzepatide, integrating this knowledge into routine clinical practice. This review signals a pressing need for updated clinical guidelines and increased awareness regarding potential drug-induced xerostomia, taste alterations, salivary gland dysfunction, or other oral manifestations that could impact patient quality of life and oral disease progression. It underscores the importance of a multidisciplinary approach, where systemic medication profiles are thoroughly considered during routine dental and oral health assessments. Furthermore, this work highlights critical avenues for future research, including mechanistic studies into how GLP-1R and GIP-R activation might directly or indirectly influence oral tissues, salivary composition, or the oral microbiome, guiding the development of specific preventive and therapeutic strategies for patients on these increasingly common medications.
tirzepatide
oral-health
review
glp-1-agonist
gip-agonist
diabetes
